Risk factor analysis for extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections in central Taiwan by Chang-Hua Chen & Chieh-Chen Huang
Chen and Huang BMC Infectious Diseases 2013, 13:417
http://www.biomedcentral.com/1471-2334/13/417RESEARCH ARTICLE Open AccessRisk factor analysis for extended-spectrum
β-lactamase-producing Enterobacter cloacae
bloodstream infections in central Taiwan
Chang-Hua Chen1,2 and Chieh-Chen Huang3*Abstract
Background: Enterobacter cloacae (E.cloacae) bloodstream infection (EcBSI) is an important cause of morbidity and
mortality, with an increasing incidence in our hospital. We wanted to elucidate the risk factors of mortality among
patients with ESBL-positive EcBSI in central Taiwan.
Methods: We ordered the clinical and microbiological data of cases with diagnosis of EcBSI, and analyzed the
isolates by using antibiotyping, detection of ESBL, detection of class 1 integron and genomic fingerprinting by
pulsed-field gel electrophoresis (PFGE).
Results: Seventy episodes of EcBSI from 70 patients (56 hospital-acquired infections) were enrolled. Significant
differences were found between ESBL-positive and ESBL-negative isolates with regard to risk factors, including the
diseases severity (p = 0.03), category of health care-associated infection (p = 0.04), prior use of antibiotics (p = 0.023), and
prior use of a ventilator (p = 0.037). A significant difference in mortality between two groups (p = 0.004) was determined
using the chi-square test, and a trend in mortality between two groups (p = 0.006, OR = 4.750, 95% C.I.=1.573-14.344)
was determined using univariate logistic regression analysis. The predominant clone in ESBL-positive strains was
associated with a higher mortality rate but not with the presence of the integron.
Conclusions: The study disclosed four types of clinical characteristics to obtain ESBL-positive EcBSI, and there was a
trend in mortality too. We suggested the need to review antibiotic prescription practices, and the possible need to
consider ESBL-positive strains in empirical treatment of bloodstream infection.
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Bloodstream infectionsBackground
Enterobacter cloacae (E. cloacae) is the most frequently
isolated species of Enterobacter, which is a genus within
the family Enterobacteriaceae [1] that causes infections
in hospitalized and debilitated patients and has emerged
as an important bacterial pathogen in recent years [2]. E.
cloacae bloodstream infection (EcBSI) is an important
cause of morbidity and mortality in both developing and
developed countries, especially Taiwan [3,4].
In the last 20 years, extended-spectrum β-lactamases
(ESBLs) have attained great medical importance [5]. With* Correspondence: cchuang@dragon.nchu.edu.tw
3College of Life Science, National Chung Hsing University, No. 250 Kuo-
Kuang Road, Taichung 40227, Taiwan
Full list of author information is available at the end of the article
© 2013 Chen and Huang; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumregard to the expression mechanism, bacterial class 1
integrons, such as IntI1 integron, contain a site-specific re-
combination system able to capture and express genes as
gene cassettes [6], and most cassette-integrated β-lactamase
genes, such as blaVEB-1 and blaGES-1, encode β-lactamases
[7,8]. Jiang et al. found that 12 clonally related E. cloacae
isolates from the China possessed a novel blaVEB-3-type
beta-lactamase that was located in an integron [9], and
some studies have reported that Taiwan E. cloacae strains
contain the bla Imp-8 and bla SHV-12 genes [3,4].
The isolation rate of E. cloacae has increased since 1995
at the hospital in Taiwan evaluated in the present study.
Preliminary findings suggested an increased prevalence of
E. cloacae that was associated with high mortality from E.
cloacae infection and high prevalence of the IntI1ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ESBLs and integrons of E. cloacae. We collected the clin-
ical and microbiological data of cases with a diagnosis of
EcBSI and analyzed the isolates by antibiotyping, detection
of ESBLs, detection of the class 1 integron and genomic
fingerprinting by pulsed-field gel electrophoresis (PFGE).
The goal of the study was to elucidate the risk factors for
mortality among patients with ESBL-positive EcBSI in
central Taiwan.
Methods
Hospital setting and data collection
The study hospital is an 1800-bed teaching hospital lo-
cated in the center of Changhua in central Taiwan. A
cross-sectional retrospective study of EcBSI was
conducted by the division of infectious diseases of the
study hospital from January 1, 2001 through December
31, 2003. The clinical details were recorded, and any
mention of risk factors (only those predating the infec-
tion) was recorded. The severity of the underlying dis-
ease was categorized using the criteria of McCabe &
Jackson [10]. The source of infection was determined
according to clinical and microbiological evidence and
categorized according to its site of origination. All pa-
tients with documented EcBSI at the hospital were en-
rolled during the study period. Repeated isolation of E.
cloacae within a two-week period was defined as one
episode of EcBSI. Only the first isolate obtained from each
patient was studied. The exclusion criteria included inad-
equate data and misidentification. The ESBL-positive and
ESBL-negative groups were defined according to the
microbiological reports. The integron groups were defined
according to the results of IntI1 gene detection. Health
care-associated infection (HAI) was defined according to
criteria of the Center of Disease Control and Prevention
(CDC) [11]; in particular, HAI was defined when all CDC-
defined conditions for site-specific infection were first
present together on or after the third day of admission in
the hospital.
Ethical approval
The collection of these data as described above was ap-
proved by the Ethics Committee of Changhua Christian
Hospital (the reference number is CCH 121,112).
Microbiological investigation
Blood cultures were performed for every patient with
suspected sepsis using the BACTEC NR-860 system (Becton
Dickinson Diagnostic Instrument Systems, Franklin Lake,
NJ). E. cloacae was presumptively identified using colonial
morphology, Gram staining and routine biochemical reac-
tions, and the identification was confirmed using the API-
20NE kit (Bio Merieux Vitek, Hazelwood, Mo). Routine
antibiotic sensitivity testing using β-lactams (amoxicillin-clavulanate, piperacillin-tazobactam, cefazolin, cefuroxime,
flomoxef, cefotaxime, ceftriaxone, ceftazidime, cefepime
and imipenem-cilastatin), aminoglycosides (amikacin, genta-
micin and tobramycin), fluoroquinolones (ciprofloxacins and
ofloxacin) and trimethoprim-sulfamethoxazole was performed
using the disk diffusion method (BBL, Sensi-Disc; Becton
Dickinson, Cockeysville, MD), according to the guidelines of
the Clinical and Laboratory Standards Institute (CLSI) [12].
Antimicrobial susceptibility testing for confirmation and de-
tection of ESBLs was performed on the Vitek-2 System
(Biomerieux, Hazlewood, Mo.), which has been shown to be
99% sensitive and specific for the detection of ESBLs [13].
Molecular detection of IntI1
Polymerase chain reaction (PCR) was performed for all E.
cloacae for detection of IntI1. Koeleman’s previously de-
scribed method was used to amplify the target genes [14].
IntI1 F (5′-CAGTGGACATAAGCCTGTTC-3′) and R
(5′-CCCGAGGCATAGACTGTA-3′) primers were used
to detect the IntI1 gene. PCR amplification was conducted
in 20-μL volumes containing 0.25 μL template DNA,
0.025 mM deoxynucleoside triphosphate (dNTP), 1 μL
10 K PCR buffer, 1U Taq polymerase (Perkin-Elmer Ap-
plied Biosystems, Foster City, CA), 1.5 mMMgCl2 and each
primer at a concentration of 0.5 μM. PCR amplification
was performed using a PTC-200 Gradient Peltier Thermal
Cycler (MJ Research, Waltham, MA). The amplification
products were resolved by electrophoresis at 125 V for 1 h
on a 1.5% agarose gel in 0.5 × Tris-borate-EDTA buffer
containing ethidium bromide, followed by visualization
under UV light. All PCR amplifications were performed in
duplicate.PFGE analysis
Genomic DNA isolated from E. cloacae was digested using
XbaI (Takara Bio Co., Japan), and the standard PFGE proto-
col for E. cloacae was followed according to Fernández’s
procedure [15]. Briefly, E. cloacae isolates were grown on
blood agar plates incubated in 5% CO2 at 35°C for 16 to
24 h. Plug slices with a width of 2 mm were digested using
20 U of XbaI. The DNA fragments were then separated in
1% Seakem Gold agarose gel (FMC BioProducts) at 14°C
using a Bio-Rad CHEF DRIII (Bio-Rad Laboratories) in
0.5 × Tris-borate-EDTA (TBE; pH 8) at a 120° fixed angle
using a fixed voltage (6 V/cm) and pulse time intervals
from 2.2 to 54.2 s for 22 h. XbaI-digested genomic DNA
fragments of S. enterica ser. Braenderup H9812 were used
as reference size markers. After staining and destaining of
the gel, it was exposed on a LJV transilluminator, and the
image was captured digitally using a gel documentation sys-
tem (Alphalmager 2000; Alpha Innotech Corporation, San
Leandro, Calif.). The interpretation criteria were described
previously by Tenover [16].
Table 1 Analysis of the risk factors between 20 patients
with ESBL-positive EcBSI and 50 patients with
ESBL-negative EcBSI
ESBL-negative
E. cloacae
ESBL-positive
E. cloacae
p-
value
Total number Total number
Underlying disease
Diabetes mellitus 14 6
Liver cirrhosis 5 2
Cancer 12 5
Uremia 3 1
McCabe category A 19 5 0.03
B 19 5
C 12 10
Belong to Health care-
associated infection
36 20 0.04
Invasive procedures before
E. cloacae infection
4 20 0.481
Chemotherapy before
E. cloacae infection
1 2 0.482
Operation before
E. cloacae infection
15 1 0.481
Usage of central venous
catheter before
E. cloacae infection
50 20 0.464
Usage of peripheral catheter
before E. cloacae infection
50 20 0.301
Usage of arterial catheter
before E. cloacae infection
24 18 0.857
Usage of Swan-Guan
catheter before
E. cloacae infection
4 3 0.481
Usage of total parenteral
nutrition before
E. cloacae infection
35 17 0.65
Usage of antibiotics
before E. cloacae infection
46 17 0.023
Usage of ventilator before
E. cloacae infection
47 19 0.037
Usage of Foley catheter 42 20 0.657
P-value by chi-squared test or Fisher’s exact test when appropriate.
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Either the chi-squared test or Fisher’s exact test was
used for analysis. The results were considered significant
when P < 0.05. All data were analyzed using SPSS soft-
ware v10.0.
Results
Eighty patients with a diagnosis of EcBSI were identified
during the study period, but 10 patients were excluded be-
cause of inadequate data. Seventy-eight E. cloacae isolates
were recovered from the remaining 70 patients, and only
the first isolate obtained from each patient was studied.
Fifty-six of the EcBSI isolates were identified as HAI, and
the remainder was undefined because the patients were
referred from either a local hospital or the community.
Overall, 20 of 70 E. cloacae isolates possessed ESBL, and
49 of them possessed the IntI1 gene.
The demographics of the 20 patients with ESBL-positive
EcBSI are presented in Additional file 1. The male to fe-
male ratio was 8:12, and the age range was 0–82 years.
Fourteen of the 20 patients with ESBL-positive EcBSI had
fever. The initial presentation of the 20 patients included
abdominal pain(5 patients), shortness of breath(4), con-
scious disturbance(4), hematuria(2), deafness(1), flank pain
(1), chest pain(1), dysuria(1), and limb weakness(1). Three
of them developed shock at initial presentation. Only three
of them had received effective empirical antibiotic treat-
ment at the early stage of EcBSI. Twelve of the 20 patients
(60%) died. Nine of the 12 deaths directly resulted from
the EcBSI (Additional file 1).
The results of the risk factor analysis are listed in Table 1.
There was a significant difference between the ESBL-
positive and ESBL-negative groups with regard to disease
severity (p = 0.03), category of HAI (p = 0.04), prior use of
antibiotics (p = 0.023) and prior use of a ventilator (p =
0.037). Table 2 shows the analysis of the clinical presenta-
tion in patients with ESBL-positive and ESBL-negative iso-
lates. In patients with ESBL-negative isolates, the male to
female ratio was 29:21. Overall, urinary tract infection was
the only factor significantly different between patients with
ESBL-positive isolates and those with ESBL-negative iso-
lates, either in clinical presentation or microbiological
characteristics. As shown in Table 3, there was a signifi-
cant difference in mortality between patients with ESBL-
positive isolates and those with ESBL-negative isolates
(p = 0.004), and mortality tended to be different between
patients with ESBL-positive isolates and those with ESBL-
negative isolates (p = 0.006, OR = 4.750, 95% C.I.=1.573-
14.344) in the univariate logistic regression analysis.
Forty-nine of the 70 isolates (70%) carried the IntI1 gene,
and 18 of the 49 patients (36.7%) with these isolates died.
There was no significant difference between patients with
integron-positive E. cloacae and those with integron-
negative isolates (Table 3).All 13 strains tested (11 ESBL-positive and 2 ESBL-
negative) were typeable. Ten ESBL-positive isolates from
expired patients and one each from an ESBL-positive iso-
late from a survivor, an ESBL-negative isolate from an ex-
pired patient and an ESBL-negative from a survivor were
analyzed to investigate differences in clinical outcome be-
tween ESBL-positive and ESBL-negative strains and to es-
tablish the major clones. The fingerprints generated using
XbaI restriction endonucleases are shown in Figure 1.
There was no evidence of clonal dissemination during the
three years of the study. The predominant clone was
found in most of the ESBL-positive strains.
Table 2 Clinical presentation between ESBL-positive EcBSI and ESBL-negative EcBSI
ESBL(−) ESBL(+) P-value
Integron
(−)
Integron
(+)
Integron
(−)
Integron
(+)
Total N % N % P-value Total N % N % P-value
Sex Male 29 9 31.0 20 69.0 0.851 8 2 25.0 6 75.0 1.000 1.000
Female 21 6 28.6 15 71.4 12 4 33.3 8 66.7 1.000
Previous antibiotics at the
empirical stage before
No 24 1 5.0 23 95.0 1.000 17 7 41.2 10 58.8 1.000 0.023
E. cloacae infection Yes 26 16 61.0 10 39.0 3 1 33.3 2 66.7
Prognosis Survival 38 18 47.4 20 52.6 0.874 8 2 25.0 6 75.0 1.000 0.435
Expired 12 6 50.0 6 50.0 12 2 16.7 10 83.3 0.193
Type of infection Primary 1 0 0.0 1 100.0 1.000 5 2 0.0 3 100.0 1.000
Secondary 49 9 18.4 40 81.6 15 4 21.1 11 78.9 1.000
Secondary infection (multiple) Total 49 19 30 15 5 10
Respiratory tract 30 10 33.3 20 66.7 0.326 3 1 33.3 2 66.7 0.370 1.000
Urinary tract 12 2 16.7 10 83.3 0.095 6 1 5 0.023 1.000
Catheter-related 2 0 0.0 2 100.0 0.515 0 0 0.0 0 100.0 1.000
Intra-abdominal infection 9 2 22.2 7 77.8 0.451 6 0 0.0 6 100.0 0.474 1.000
CNS infection 3 1 33.3 2 66.7 1.000 0 0 0.0 0 0.0
Others 3 1 33.3 2 66.7 1.000 0 0 0.0 0 00 0.474 1.000
P-value by chi-squared test or Fisher’s exact test when appropriate.
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E. cloacae bloodstream infection is an important cause
of morbidity and mortality in both developing and devel-
oped countries. In our hospital, an increasing incidence
and a high crude mortality rate (24/70, 34.3%) led us to
investigate the epidemiology of this infection, particu-
larly with regard to ESBL, and to determine whether
clonal spreading occurred.
In a previous epidemiological study of E. cloacae in-
fection, Liu showed that central venous catheterization
and mechanical ventilation increased the relative risk
for nosocomial E. cloacae infection; that age and mech-
anical ventilation were risk factors for multiresistant E.
cloacae infection; and that mortality was associated with
multiresistant isolates and polymicrobial infection [4].
These risk factors were similar to those identified in ourTable 3 Univariate logistic regression analysis for mortality b
Total Expired P-
value*N %
Overall ESBL(−) 50 12 24.0 0.004 1
ESBL(+) 20 12 60.0
ESBL(−) Integron(−) 24 6 25.0 0.874 −
Integron(+) 26 6 23.1
ESBL(+) Integron(−) 4 2 50.0 1.000 0
Integron(+) 16 10 62.5
*:by chi-squared test or Fisher’s exact test when appropriate.
OR: odds ratio.study, which included disease severity (p = 0.03), cat-
egory of hospital-acquired infection (p = 0.04), prior use
of antibiotics (p = 0.023) and prior use of a ventilator
(p = 0.037). We also demonstrate that mortality tended
to be different (p = 0.006, OR = 4.750, 95% C.I.=1.573-
14.344) between infections with ESBL-positive E. clo-
acae and those with ESBL-negative E. cloacae.
ESBL-expressing E. cloacae present a challenge for clin-
ical microbiologists and clinicians because of the high
morbidity and mortality associated with infection. In our
study, some ESBL-positive stains were sensitive to
imipenem-cilstatin. However, there have already been re-
ports of therapeutic failures of imipenem-cilstatin in
strains that produce multiple β-lactamases [17]. The high
mortality rate observed for ESBL-positive EcBSI likely re-
sults from this difficulty in treatment. In the present study,etween ESBL-positive EcBSI and ESBL-negative EcBSI
Univariate logistic regression analysis
B SE OR 95% CI for OR P-value
.558 0.564 1.000 1.573 - 14.344 0.006
4.750
0.105 0.662 1.000 0.246 - 3.297 0.874
0.900
.511 1.125 1.000 0.184 - 15.130 0.650
1.667
Figure 1 PFGE fingerprints of 11 ESBL(+) E. cloacae isolates and 2 ESBL(−) E. cloacae isolates after digestion with the XbaI restriction
enzyme. Lane 1 to lane 10, ESBL(+) E. cloacae isolates; lane 11 to lane 13, ESBL(−)E. cloacae isolates; lane M, molecular size markers (PFGE marker,
S. enterica ser.Braenderup H9812).
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patients with ESBL-positive EcBSI and those with
ESBL-negative EcBSI (p = 0.004), and mortality tended
to be different between patients with ESBL-positive
EcBSI and those with ESBL-negative EcBSI (p = 0.006,
OR = 4.750, 95% C.I. = 1.573-14.344) in a univariate
logistic regression analysis. These findings may be at-
tributed to the fact that 17 of the 20 patients with
ESBL-positive EcBSI did not receive effective empirical
antibiotic treatment, whereas 46 of the 50 patients with
ESBL-negative isolates did receive effect antibiotic
treatment.
This is the first study to report the relationship between
ESBLs and an integron in E. cloacae. There was no signifi-
cant difference between patients with integron-positive
EcBSI and those with integron-negative EcBSI. However,
mortality tended to be different between patients with
ESBL-positive EcBSI and those with ESBL-negative EcBSI
(p = 0.004). The development and spread of ESBL-positive
EcBSI has been suggested to be caused by the overuse
of expanded-spectrum cephalosporins in the hospital
setting [3]. We agree with this mechanism but also con-
sider that the epidemiology of ESBL-positive EcBSI
requires further investigation. We observed a high
prevalence (70%) of the integron, which also raises the
question of whether antibiotic selective pressure in hos-
pitals in Taiwan may have led to the dissemination of
this integron, which contains an ESBL-carrying cassette.
β-lactam, aminoglycoside and sulfonamide resistance
genes are all associated with class 1 integrons and may
enhance the dissemination of these integrons. Similar to
Severino [18], we suggest that integron detection should
be used for the study of molecular epidemiology in hos-
pital environments, particularly for the detection of
possible cross-infection cases and estimation of accu-
mulative antibiotic selective pressure.The increased prevalence of E. cloacae and its associ-
ation with high EcBSI mortality and high prevalence of
IntI1 motivated us to perform PFGE, which is an auxiliary
investigation method for E. cloacae isolates that has high
reproducibility and high discriminatory power and is thus
regarded as the “gold standard” for defining a clone in
various nosocomial bacterial populations [2,19]. The pre-
dominant clone was associated with increased mortality
that was most likely related to ESBL production; however,
the predominant clone was not associated with the pres-
ence of the integron. Clonal spread was not observed, and
the class 1 integron was not a major factor in the in-
creased incidence of ESBL-positive E. cloacae in the study
hospital. Ho et al. used PFGE genotyping to show that
seven ESBL- positive E. hormaechei isolates were unre-
lated [20]. Our results are similar and show a lack of
clonal outbreak during the three years of the study. The
predominant clone seemed to be associated with increased
mortality and ESBL expression but not with the presence
of the integron.
Although the bacterial isolates were collected between
2001 and 2003, as the clinical pattern of EcBSI did not
show obvious changes in our institute within the last dec-
ade (2002–2012), the results are still relevant for clinical
application at the present time and agree with the findings
of Freeam [21].
Conclusions
This study identified four types of clinical characteris-
tics for ESBL-positive EcBSI, and increased mortality
was associated with the presence of ESBL, which most
likely resulted from inappropriate empirical treatment.
We suggest that it is necessary to review antibiotic
prescription practices and possibly consider ESBL-
positive strains in the empirical treatment of blood-
stream infections.
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